Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P50995
UPID:
ANX11_HUMAN
Alternative names:
56 kDa autoantigen; Annexin XI; Annexin-11; Calcyclin-associated annexin 50
Alternative UPACC:
P50995; B4DVE7
Background:
Annexin A11, also known as a 56 kDa autoantigen, Annexin XI, and Calcyclin-associated annexin 50, plays a crucial role in cellular processes. It binds specifically to calcyclin in a calcium-dependent manner, a key interaction for midbody formation and successful completion of cytokinesis. This protein's involvement in cell division underscores its fundamental importance in biology.
Therapeutic significance:
Annexin A11's association with diseases such as Amyotrophic lateral sclerosis 23 and Inclusion body myopathy with brain white matter abnormalities highlights its potential as a therapeutic target. Understanding the role of Annexin A11 could open doors to potential therapeutic strategies, especially considering its involvement in neurodegenerative disorders and muscle weakness conditions.